Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01380366 · ClinicalTrials.gov registry record · Phase 4
rHGH and Intestinal Permeability in Intestinal Failure
A Phase 4 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT01380366 is a Phase 4 study that has completed, run by Northwestern University. The registered enrollment target is 15 participants.
The verdict
NCT01380366, a Phase 4 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Patients who are being asked to participate in this study have a short small bowel and will be prescribed to take the medication: Zorbtive® ("Zorbtive/Somatropin/(rHGH)"). Zorbtive® is an FDA approved recombinant human growth hormone (rHGH). The investigators want to see if taking this medication improves small bowel function by helping it to take in food, nutrients, vitamins and minerals. The investigators also believe that if the small bowel is absorbing food and nutrients better, liver function will improve as well. Therefore, liver function will also be monitored during the course of the study by performing blood tests.
Interventions
- OTHER Fasting
- DRUG Somatropin
- PROCEDURE Seven Day Food Diary
- PROCEDURE Blood Tests (standard of care)
- OTHER Sugar Permeability Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-10 |
| Est. Completion | 2015-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01380366
The ClinicalTrials.gov registry entry for NCT01380366 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fasting is the first listed.
NCT01380366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01380366 about?
NCT01380366 is a clinical study titled "rHGH and Intestinal Permeability in Intestinal Failure". Patients who are being asked to participate in this study have a short small bowel and will be prescribed to take the medication: Zorbtive® ("Zorbtive/Somatropin/(rHGH)"). Zorbtive® is an FDA approved recombinant human growth hormone (rHGH). The investigators want to see if taking this medication im...
What is the current status of trial NCT01380366?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2006-10. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01380366?
The interventions under investigation include: Fasting (OTHER), Somatropin (DRUG), Seven Day Food Diary (PROCEDURE), Blood Tests (standard of care) (PROCEDURE), Sugar Permeability Test (OTHER).
Who is sponsoring clinical trial NCT01380366?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.